Tesamorelin vs Ipamorelin: GHRH vs GHRP Research Comparison
Tesamorelin vs Ipamorelin: GHRH vs GHRP Research Comparison
Research peptides for laboratory use only. Not approved by the FDA. Not for human consumption. By purchasing, you confirm you are a qualified researcher operating in a controlled laboratory setting.
Overview
Tesamorelin and ipamorelin are commonly compared because both appear in growth-hormone-axis research, but they sit in different receptor families and answer different research questions. Tesamorelin is a growth-hormone-releasing-hormone (GHRH) analog. Ipamorelin is a growth-hormone-releasing-peptide (GHRP). They are not interchangeable, and a research design selecting between them should match the receptor family to the research question. This guide walks through the receptor contrast, the half-life and structural differences, the research-context applications for each, and the Pure Chain Aminos SKUs available.
GHRH Analog vs GHRP
Tesamorelin (GHRH analog)
Tesamorelin is a 44-amino-acid synthetic analog of growth-hormone-releasing-hormone (GHRH), modified at the N-terminus to resist enzymatic degradation. It binds the GHRH receptor (GHRHR) on anterior pituitary somatotrophs, the same receptor engaged by endogenous GHRH. The structural strategy in tesamorelin is N-terminal modification preserving GHRHR engagement while extending plasma half-life relative to native GHRH.
The published preclinical and clinical literature for tesamorelin emphasizes the GHRHR-axis activation profile and its associated effects on the GH and IGF-1 axis in research models.
Ipamorelin (GHRP)
Ipamorelin is a synthetic pentapeptide in the growth-hormone-releasing-peptide class. It binds the growth hormone secretagogue receptor (GHSR-1a), a separate receptor from GHRHR. Ipamorelin is selective at GHSR-1a in the sense that published preclinical work indicates it does not produce the prolactin or cortisol elevations characteristic of earlier GHRP-class peptides.
Receptor Families: Why It Matters
GHRHR and GHSR-1a are different receptors with different downstream-signaling cascades and different physiological-context cues for activation. Endogenous GHRH and endogenous ghrelin engage them independently in normal physiology, and the two receptor systems integrate at the somatotroph level to produce the pulsatile GH-release pattern observed in animal models.
For research operators, this means that tesamorelin and ipamorelin are not substitutes. They are mechanistically distinct interventions on the GH axis, and a research design comparing them should treat them as orthogonal tools. Studies of GHRHR-axis activation use tesamorelin. Studies of GHSR-1a-axis activation use ipamorelin. Studies of combined-pathway activation use both.
Half-Life Comparison
Tesamorelin: half-life on the order of 30-40 minutes in published preclinical work, extended relative to native GHRH (minutes) by N-terminal modification.
Ipamorelin: half-life on the order of 1-2 hours in published preclinical work.
Both are pulse-friendly half-life profiles for research designs sampling GH dynamics on a sub-daily cadence.
Research Applications
Tesamorelin sits in research lineages that emphasize GHRH-axis-specific intervention, where the research question targets GHRHR engagement and its downstream effects. Ipamorelin sits in research lineages that emphasize ghrelin-axis-specific intervention, where the research question targets GHSR-1a engagement and the pulsatile-release profile that follows.
The combination tesamorelin + ipamorelin appears in research literature when the research question is the additive or synergistic effect of dual-pathway GH-axis activation. Pure Chain Aminos carries a combination SKU for this purpose.
Side-by-Side Spec Comparison
| Spec | Tesamorelin | Ipamorelin |
|---|---|---|
| Class | GHRH analog | GHRP |
| Receptor | GHRHR | GHSR-1a |
| Sequence length | 44 amino acids | 5 amino acids |
| Approximate molecular weight | ~5,196 Da | ~712 Da |
| Half-life class | ~30-40 min | 1-2 hours |
| Endogenous analog | GHRH | Ghrelin |
| PCA vial sizes | 10mg, 11mg combo | 5mg |
Reconstitution Math
Tesamorelin 10mg: reconstituted with 2 mL of bacteriostatic water yields 5 mg/mL, or 5,000 mcg/mL. A 0.1 mL draw is 500 mcg. With 1 mL, 10 mg/mL.
Ipamorelin 5mg: reconstituted with 1 mL yields 5 mg/mL. A 0.05 mL draw is 250 mcg.
Tesamorelin 11mg / Ipamorelin 6mg combo: reconstituted with 2 mL yields 5.5 mg/mL tesamorelin and 3 mg/mL ipamorelin. A 0.1 mL draw is 550 mcg tesamorelin and 300 mcg ipamorelin.
These figures are arithmetic conversions of label mass to per-volume concentration for research compounding records. They are not protocol guidance.
PCA SKUs in This Category
For researchers studying the GHRP + GHRH-analog combination from a different angle, see the Ipamorelin vs CJC-1295 comparison, which covers the more common GHRP + GHRH-analog stack.
Documentation Standard
Every Tesamorelin and Ipamorelin lot shipped from Pure Chain Aminos carries a per-batch certificate of analysis with HPLC purity verification and mass spectrometry identity confirmation. Lot identifier on the COA matches the bottle. Method documentation is on the COA.
Get Started With WELCOME20
New researchers receive 20% off their first qualifying order with code WELCOME20 ($75 minimum). Browse Tesamorelin 10mg, Ipamorelin 5mg, and the combo SKU, or browse the full Pure Chain Aminos catalog.
Research peptides for laboratory use only. Not approved by the FDA. Not for human consumption. By purchasing, you confirm you are a qualified researcher operating in a controlled laboratory setting.
Mechanism Comparison Table
Tesamorelin and ipamorelin are both growth-hormone-axis research peptides studied in laboratory models, but they engage distinct receptor families. The summary table below frames how researchers contrast the two compounds.
| Attribute | Tesamorelin | Ipamorelin |
|---|---|---|
| Compound class | 44-residue stabilized GHRH analog | Pentapeptide ghrelin-receptor agonist |
| Approximate molecular mass | ~5135 Da | ~712 Da |
| Receptor family | GHRH receptor (GHRH-R) — pituitary somatotrope GH-release pathway in animal models | Ghrelin receptor (GHS-R1a) — distinct pituitary somatotrope GH-release pathway in animal models |
| Reported half-life (animal model literature) | ~26-38 minutes systemic; longer pituitary action than native GHRH | ~2 hours systemic (short-pulse profile) |
| Common research-protocol pairing | Often paired with a ghrelin-receptor agonist to model dual-pathway pulsatile dynamics | Often paired with a GHRH analog (such as tesamorelin or CJC-1295) for the same reason |
Reconstitution Math Worked Example
Worked example assuming each lyophilized vial is reconstituted with 2 mL of bacteriostatic water. Researchers should always verify against COA-stated peptide content.
Tesamorelin 10mg vial + 2 mL bac water: 10 mg / 2 mL = 5 mg/mL = 5,000 mcg/mL. A 0.10 mL draw represents 500 mcg. A 0.05 mL draw represents 250 mcg.
Ipamorelin 5mg vial + 2 mL bac water: 5 mg / 2 mL = 2.5 mg/mL = 2,500 mcg/mL. A 0.10 mL draw represents 250 mcg.
Tesamorelin 11mg + Ipamorelin 6mg combo (Pure Chain Aminos combo SKU) + 2 mL bac water: Combined 17 mg / 2 mL = 8.5 mg/mL of combined peptide. The COA reports the per-peptide split for that lot — researchers running protocols that need to track each peptide separately should refer to that COA.
The Pure Chain Aminos bacteriostatic water reconstitution guide walks through volume selection step by step.
Stability and Storage Comparison
Both peptides are shipped lyophilized in sealed glass vials and held at 2-8 C until reconstitution. After reconstitution with bacteriostatic water, both are kept refrigerated and most cited research protocols use the reconstituted vial within 14-30 days. Tesamorelin is generally reported as stable in solution under cold storage. The combo SKU should be aliquoted into working volumes for long protocols to limit freeze-thaw cycling on either peptide.
Research Literature Snapshot
The selected references below are commonly cited in tesamorelin and ipamorelin research planning. Citations are provided for literature awareness only and make no efficacy claim.
- Falutz J et al. Effects of tesamorelin (TH9507) on visceral adipose tissue. AIDS, 2008. PMID: 18753925.
- Stanley TL, Grinspoon SK. Effects of growth hormone-releasing hormone on visceral fat in HIV-associated lipodystrophy research. Endocrinology and Metabolism Clinics of North America, 2014 (review). PMID: 25169565.
- Raun K et al. Ipamorelin, the first selective growth hormone secretagogue. European Journal of Endocrinology, 1998. PMID: 9849823.
- Sigalos JT, Pastuszak AW. The safety and efficacy of growth hormone secretagogues. Sexual Medicine Reviews, 2018. PMID: 28526581.
- Bowers CY. Pulsatile growth hormone release in response to combined ghrelin-receptor and GHRH-receptor stimulation. Journal of Pediatric Endocrinology and Metabolism, 1998. PMID: 9789344.
Researcher Considerations
Tesamorelin is more frequently selected in research models studying GHRH-receptor pathway activation, visceral-adipose research designs cited in the published literature, or models seeking longer pituitary action than native GHRH. Ipamorelin is more frequently selected in research models studying selective ghrelin-receptor agonism with minimal cortisol or prolactin pathway crosstalk in cited rodent studies. Many research designs pair the two pathways to model dual-pathway pulsatile growth-hormone-axis dynamics — which is why the combo SKU exists. Selection should follow the design hypothesis and the published reference protocol the laboratory is replicating.
FAQ
Are tesamorelin and ipamorelin the same class of peptide?
No. Tesamorelin is a stabilized GHRH analog. Ipamorelin is a ghrelin-receptor agonist. Both have research interest in pituitary GH-axis biology but engage distinct receptor families.
How do tesamorelin and CJC-1295 differ as GHRH analogs?
Both are GHRH-receptor analogs. Tesamorelin is a 44-residue molecule with a longer pituitary action profile than native GHRH. CJC-1295 (no DAC) is a 30-residue analog with a shorter half-life. The DAC-bearing CJC-1295 variant has an extended multi-day half-life via albumin binding.
Why is the combo SKU (tesamorelin + ipamorelin) commonly studied?
Pairing a GHRH analog with a ghrelin-receptor agonist allows researchers to model dual-pathway pulsatile growth-hormone-axis dynamics in cited animal model literature.
How are these peptides stored before reconstitution?
Lyophilized vials are stored at 2-8 C, sealed, away from light. After reconstitution with bacteriostatic water, vials are kept refrigerated and most cited protocols use them within 14-30 days.
Are these peptides FDA approved?
Tesamorelin is approved as a prescription drug (Egrifta) in a clinical context outside the research-grade reference space. Pure Chain Aminos sells research-grade reference peptides for laboratory use only — not as drug products. Ipamorelin is not FDA approved.
Where can I review published research?
Start with PubMed using the search terms “tesamorelin,” “ipamorelin,” “CJC-1295,” and “growth hormone secretagogue.” Pure Chain Aminos vendor research pages link to selected citations.
Selected SKU Options
Pure Chain Aminos research-grade SKUs in this category include Tesamorelin 10mg, Ipamorelin 5mg, the Tesamorelin 11mg + Ipamorelin 6mg combo, and the related CJC-1295 no DAC + Ipamorelin 10mg combo. For more on vendor selection, see how to evaluate a research peptide vendor and Ipamorelin vs CJC-1295.
Compliance reminder: research peptides for laboratory use only. Not for human consumption. Citations support literature awareness, not efficacy claims.
